Pelthos Signs First Big Deal to Expand Access to Its At-Home Treatment for Molluscum

Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced it has signed its first commercial agreement to expand patient access for ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older ("ZELSUVMI").

Pelthos has entered into an agreement with a Group Purchasing Organization that collaborates with manufacturers on behalf of one of the largest Pharmacy Benefit Managers ("PBMs") in the United States. The PBM manages prescription drug benefits for more than 20 million covered lives, and the formulary inclusion updates for ZELSUVMI started on December 1, 2025.

"Partnering with a national pharmacy benefit manager is another important milestone in our efforts to achieve increased commercial coverage for ZELSUVMI," said Scott Plesha, CEO of Pelthos. "This new partnership will allow an important treatment option to be included in more coverage and distribution networks, thereby improving access for patients and caregivers who are seeking an at-home treatment for molluscum contagiosum."

Pelthos launched ZELSUVMI for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older in July 2025. ZELSUVMI is a novel, topical nitric oxide-releasing gel for the treatment of molluscum. The once-daily prescription medication is effective, well-tolerated, and convenient for at-home or on-the-go application and can be used to treat molluscum contagiosum infections on the body, including sensitive areas such as the face, groin, or underarms. ZELSUVMI received a Novel Drug designation from the U.S. Food and Drug Administration in January 2024 and is the first and only prescription therapy approved for use at home by patients, parents, and caregivers to treat molluscum infections.

"This PBM partnership supports our overall patient services plan for ZELSUVMI. We are committed to reducing barriers for patients and providing access to our novel medication ZELSUVMI for those patients suffering from molluscum," said Sai Rangarao, Chief Commercial Officer at Pelthos.